Side-by-side comparison of AI visibility scores, market position, and capabilities
Joyn Bio engineers microbes that colonize cereal crop roots and fix atmospheric nitrogen, aiming to eliminate synthetic nitrogen fertilizer dependency in corn and wheat.
Joyn Bio is an agricultural biotechnology company founded in 2017 as a joint venture between Ginkgo Bioworks and Bayer to engineer nitrogen-fixing microbes for cereal crops. The company uses synthetic biology tools from Ginkgo's platform to design and optimize bacteria that establish stable associations with corn, wheat, and other grass crops, fixing atmospheric nitrogen in a way that legumes achieve naturally but grasses do not. Eliminating or dramatically reducing synthetic nitrogen fertilizer in cereal crops would represent one of the most significant advances in sustainable agriculture given that nitrogen fertilizer production consumes roughly 1% of global energy and contributes substantially to greenhouse gas emissions through both manufacturing and field application. Joyn Bio is conducting field trials to demonstrate nitrogen fixation performance in cereal crops at commercially relevant scales. The company leverages Bayer's global agricultural distribution and Ginkgo's synthetic biology platform to pursue an ambitious program that, if successful, could reshape the economics and environmental footprint of global grain production.
$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.
ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.